This article is more than 5 years old. Information may no longer be current.
21% of RA patients reached at least 80% adherence to DMARDs
Click Here to Manage Email Alerts
One-fifth of ethnically diverse and economically disadvantaged patients with rheumatoid arthritis had an overall adherence to disease-modifying antirheumatic drugs of at least 80%, according to recent study results.
Researchers electronically monitored the oral rheumatoid arthritis (RA) drug therapy intake of 107 patients (87% female) enrolled in a 2-year prospective cohort study from three publicly funded outpatient rheumatology clinics in Houston. Sixty-three percent of patients were Hispanic; 20%, African-American; and 17%, white. Sixty-five percent of patients had an income of less than $20,000 a year, and 44% did not complete high school.
The percentage of days (or weeks for methotrexate) that a patient took the proper dose prescribed by a physician determined adherence to disease-modifying antirheumatic drugs (DMARDs) and prednisone. Modified Health Assessment Questionnaire, Disease Activity Score 28 (DAS28), health-related quality of life and radiographic damage measured through the Sharp/van der Heijde scoring method assessed patient outcomes.
There was a 64% adherence for DMARD therapy and a 70% adherence for prednisone. Twenty-three patients (21%) had an average DMARD adherence of at least 80%. During a 2-year follow-up, those patients had a significantly lower DAS28 (3.28) compared with patients who were less adherent (4.09; P=.02). Nonadherent patients also had worse radiographic scores at baseline and 1 year.
“Our study is the first to measure drug adherence in RA patients over the long-term, and emphasizes the importance of following the prescribed regimen to manage their disease,” researcher Maria E. Suarez-Almazor, MD, PhD, said in a press release. “Physicians should work with patients to understand their reasons for nonadherence and discuss the importance of taking medications as prescribed to control RA symptoms and prevent disease progression.”
Click Here to Manage Email Alerts